Simple Summary
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and is often asymptomatic until late-stage disease when treatment options are limited. Surgical resection and transplantation remain the gold standard for early-stage disease. However, these are not options for those presenting in later stages or those with prohibitive surgical risk. Transarterial chemoembolization (TACE) is a first-line treatment recommendation for patients with intermediate-stage disease and advances are looking to expand treatment indications and improve outcomes. Enhanced TACE techniques with new materials and procedural methods have already shown promising results. Novel TACE combination therapies with radiation, ablation, and immunotherapy are looking to advance this area further. This review will highlight advances in TACE, summarize new prognostic models and discuss future directions with HCC treatment.
Excerpt
Note: In lieu of an abstract, this is an excerpt from the first page.
HCC is the most common primary liver cancer and the third leading cause of cancer-related death overall [...]